{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:29:05Z","timestamp":1776259745266,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd000209","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T00:00:00Z","timestamp":1297814400000}}],"reference-count":87,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000209.pub2","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T18:26:21Z","timestamp":1296843981000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Vitamin E for neuroleptic-induced tardive dyskinesia"],"prefix":"10.1002","author":[{"given":"Karla","family":"Soares-Weiser","sequence":"first","affiliation":[{"name":"Enhance Reviews Ltd; Central Office, Cobweb Buildings The Lane, Lyford Wantage UK OX12 0EE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Maayan","sequence":"additional","affiliation":[{"name":"Enhance Reviews Ltd; Central Office, Cobweb Buildings The Lane, Lyford Wantage UK OX12 0EE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McGrath","sequence":"additional","affiliation":[{"name":"Queensland Brain Institute, Queensland Centre for Mental Health Research; University of Queensland Brisbane Queensland Australia QLD 4072"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,16]]},"reference":[{"key":"10.1002\/14651858.CD000209.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0006-3223(97)00027-9","article-title":"Long-term treatment effects of vitamin E for tardive dyskinesia","volume":"43","author":"Adler","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0002|cit2","unstructured":"Adler LA Peselow E Angrist B Duncan E Lee M Rosenthal M Rotrosen J Vitamin E in tardive dyskinesia: effects of longer term treatment Proceedings of the 31st Annual Meeting of the American College of Neuropsychopharmacology; 1992 Dec 14-18; San Juan, Puerto Rico 1992"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0003|cit3","first-page":"371","article-title":"Vitamin E in tardive dyskinesia: time course of effect after placebo substitution","volume":"29","author":"Adler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"issue":"9","key":"10.1002\/14651858.CD000209.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","article-title":"Vitamin E treatment of tardive dyskinesia","volume":"150","author":"Adler","year":"1993","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archpsyc.56.9.836","article-title":"Vitamin E treatment for tardive dyskinesia","volume":"56","author":"Adler","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/0006-3223(94)91073-1","article-title":"Vitamin E treatment of TD: development of a VA cooperative study","volume":"35","author":"Adler","year":"1994","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002130050320","article-title":"Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study #394","volume":"132","author":"Caligiuri","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0008|cit8","first-page":"59","article-title":"Interrater reliability issues in multicentric trials, part II: statistical procedures used in Department of Veterans Affairs Cooperative Study #394","volume":"33","author":"Edson","year":"1997","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0009|cit9","first-page":"861","article-title":"Whither vitamin E and tardive dyskinesia?","volume":"43","author":"Lohr","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0010|cit10","first-page":"53","article-title":"Interrater reliability issues in multicentric trials, part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study 394","volume":"33","author":"Tracy","year":"1997","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0011|cit11","first-page":"124","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"39","author":"Akhtar","year":"1993","journal-title":"Journal of Postgraduate Medicine"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1176\/ajp.151.6.925","article-title":"Effectiveness of vitamin E for treatment of long-term tardive dyskinesia","volume":"151","author":"Dabiri","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0006-3223(96)00367-8","article-title":"Treatment of long-term tardive dyskinesia with vitamin E","volume":"41","author":"Dorevitch","year":"1997","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1176\/ajp.149.6.773","article-title":"Treatment of tardive dyskinesia with vitamin E","volume":"149","author":"Egan","year":"1992","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/ajp.147.4.505","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"147","author":"Elkashef","year":"1990","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005053-199402000-00009","article-title":"Vitamin E in the treatment of tardive dyskinesia: a replication study","volume":"182","author":"Lam","year":"1994","journal-title":"Journal of Nervous and Mental Diseases"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0017|cit17","first-page":"167","article-title":"A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia","volume":"57","author":"Lohr","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000209.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004850-199807000-00001","article-title":"Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses","volume":"13","author":"Sajjad","year":"1998","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S0924933800002625","article-title":"Treatment of tardive dyskinesias with vitamin E","volume":"6","author":"Schmidt","year":"1991","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004850-199705000-00008","article-title":"Lack of effect of vitamin E on serum creatine phosphokinase in patients with long-term tardive dyskinesia","volume":"12","author":"Dorevitch","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0920-9964(92)90164-Z","article-title":"Alpha-tocopherol in the treatment of tardive dyskinesia","volume":"6","author":"Junker","year":"1992","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radicals in neuroleptic induced movement disorders","volume":"570","author":"Cadet","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"8538","key":"10.1002\/14651858.CD000209.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(87)92878-9","article-title":"Alpha-tocopherol in tardive dyskinesia [letter]","volume":"1","author":"Lohr","year":"1987","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/schbul\/14.2.291","article-title":"Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms","volume":"14","author":"Lohr","year":"1988","journal-title":"Schizophrenia Bulletin"},{"issue":"8","key":"10.1002\/14651858.CD000209.pub2-BIB0025|cit25","first-page":"795","article-title":"Tardive dyskinesia","volume":"44","author":"Peet","year":"1993","journal-title":"Hospital and Community Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00004850-199300830-00003","article-title":"Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment","volume":"8","author":"Peet","year":"1993","journal-title":"International Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02684961","article-title":"Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation","volume":"7","author":"Ricketts","year":"1995","journal-title":"Journal of Developmental and Physical Disabilities"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/JCP.0b013e31819a6aa2","article-title":"Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine","volume":"29","author":"Salmasi","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/ajp.149.3.391","article-title":"Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study","volume":"149","author":"Shriqui","year":"1992","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00005053-199206000-00012","article-title":"Alpha-tocopherol treatment for tardive dyskinesia","volume":"180","author":"Spivak","year":"1992","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"6","key":"10.1002\/14651858.CD000209.pub2-BIB0031|cit31","first-page":"311","article-title":"Vitamin E in the management of drug induced tardive dyskinesia: a double blind randomized clinical trial","volume":"4","author":"Kar-Ahmadi","year":"2002","journal-title":"Journal of Research in Medical Sciences"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0033|cit33","volume-title":"Tardive dyskinesia: a task force report of the American Psychiatric Association","author":"American Psychiatric Association","year":"1992"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1991.tb05604.x","article-title":"Should we cross off the crossover?","volume":"32","author":"Armitage","year":"1991","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0035|cit35","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-079035-7.50021-X","article-title":"The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects","volume-title":"Antipsychotic drugs and their side-effects","author":"Barnes","year":"1993"},{"issue":"8","key":"10.1002\/14651858.CD000209.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.144.5.498","article-title":"Tardive dyskinesia: fluctuating patient or fluctuating rater","volume":"144","author":"Bergen","year":"1984","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000209.pub2-BIB0039|cit39","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radical in neuroleptic-induced movement disorders","volume":"570","author":"Cadet","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0041|cit41","article-title":"Tardive dyskinesia: pathophysiology","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Casey","year":"1994"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Chouinard G Chouinard VA Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes Psychotherapy and psychosomatics 2008 69 77","DOI":"10.1159\/000112883"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0043|cit43","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0044|cit44","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions [Version 5.0.2]","author":"Deeks","year":"[updated September 2009]"},{"issue":"6","key":"10.1002\/14651858.CD000209.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub2-BIB0049|cit49","first-page":"25","article-title":"Progress in the treatment of tardive dyskinesia: theory and practice","volume":"44","author":"Feltner","year":"1993","journal-title":"Hospital and Community Psychiatry"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0050|cit50","article-title":"The crossover study","volume-title":"The design and analysis of clinical experiments","author":"Fleiss","year":"1984"},{"issue":"7","key":"10.1002\/14651858.CD000209.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0053|cit53","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Revised Edition","author":"Guy","year":"1976"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub2-BIB0054|cit54","first-page":"35","article-title":"Successful prevention of tardive dyskinesia","volume":"4","author":"Hawkins","year":"1989","journal-title":"Journal of Orthomolecular Medicine"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/schbul\/19.2.303","article-title":"Tardive dyskinesia","volume":"19","author":"Jeste","year":"1993","journal-title":"Schizophrenia Bulletin"},{"issue":"7303","key":"10.1002\/14651858.CD000209.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u0171ni","year":"2001","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0058|cit58","article-title":"Positive and negative syndrome scale (PANSS) manual","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000209.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"Supplement 29","key":"10.1002\/14651858.CD000209.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000298255","article-title":"Introduction","volume":"168","author":"Lieberman","year":"1996","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub2-BIB0063|cit63","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000458","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic induced tardive dyskinesia","author":"Lyra da Silva","year":"1997","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0070|cit70","article-title":"Crossover trials","volume-title":"Clinical trials. A practical approach","author":"Pocock","year":"1983"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0071|cit71","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"1-2","key":"10.1002\/14651858.CD000209.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0952-3278(96)90149-0","article-title":"Antioxidant treatment of tardive dyskinesia","volume":"55","author":"Rotrosen","year":"1996","journal-title":"Prostaglandins, Leukotrienes and Essential Fatty Acids"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0073|cit73","first-page":"431","article-title":"The clinical research base for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206","article-title":"Diltiazem, nifedipine, nimodipine orverapamil for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0077|cit77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub2","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub2","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000209.pub2-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub2","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD000209.pub2-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD000209.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Umbrich","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000209.pub2-BIB0084|cit84","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P Pinfold V Takriti Y The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27 Sao Paulo 2007"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000209.pub2-BIB0086|cit86","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000206","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD000209.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd000209.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD000209.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T20:55:24Z","timestamp":1628542524000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD000209.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,2,16]]},"references-count":87,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000209.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD000209.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,16]]}}}